Sartorius News Release Image (2)

Sartorius Bioreactors integrate Emerson technology to speed new therapies to market

Aug. 3, 2023
DeltaV control system natively integrated into Sartorius Biostat STR bioreactors promises a foundation for semi-autonomous operations and quicker integration time.

Emerson has collaborated with Sartorius to natively integrate Sartorius’s Biostat STR Generation 3 family of bioreactors with Emerson’s DeltaV distributed control system (DCS). The Biostat STR Generation 3 for Emerson’s DeltaV, a variant of the Biostat STR Generation 3 family, is a pre-engineered solution that delivers intuitive connectivity for accelerating and simplifying the process of bringing therapies that improve patient quality-of-life to market, per its maker.

Biostat STR Generation 3 natively-integrated with a plant’s DeltaV DCS eliminates complexity for one of the most frequently used components of biopharmaceutical manufacturing. The bioreactors are specifically designed and pre-engineered with DeltaV components from the ground up by Sartorius, the partners note, adding that the configuration toolkit developed by Emerson and Sartorius has a library of templates that provide standardized configuration.

Using the library, teams can integrate bioreactors into their control system quickly and easily out of the box. Commercial manufacturing sites expect to save up to 80% of their equipment integration time, helping them take advantage of the enhanced features and diagnostics inherent in the DeltaV DCS more quickly and easily, they promise. The increased automation reduces the need for manual operation, ultimately increasing quality and speeding up time-to-market.

“One of the biggest barriers to fast delivery of new treatments is the time it takes to connect new equipment to the plant’s control system,” said Nathan Pettus, president of Emerson’s process systems and solutions business. “Working closely with Sartorius to seamlessly incorporate our DeltaV technologies and software into Sartorius bioreactors, we jointly have made one of the most critical components of biopharmaceutical manufacturing ready to connect out of the box for faster speed-to-market.”